STAAR Surgical Co. 10-Q Summary
Business Context and Reporting Period
Company: STAAR Surgical Company (STAAR)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 29, 2007
Business Overview: STAAR develops and manufactures visual implants and ophthalmic products, primarily Intraocular Lenses (IOLs) for cataract surgery and the Visian ICL for refractive correction. The company operates globally with manufacturing in the U.S. and Switzerland.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 29, 2007 |
Three Months Ended June 30, 2006 |
Six Months Ended June 29, 2007 |
Six Months Ended June 30, 2006 |
|---|---|---|---|---|
| Net Sales | $14,932 | $14,733 | $29,849 | $28,198 |
| Gross Profit | $7,237 | $7,044 | $14,532 | $13,449 |
| Gross Margin | 48.5% | 47.8% | 48.7% | 47.7% |
| Operating Loss | $(3,672) | $(3,043) | $(6,873) | $(6,253) |
| Net Loss | $(4,357) | $(3,218) | $(7,878) | $(6,581) |
| Cash & Equivalents (End of Period) | $16,082 (as of June 29, 2007) | |||
| Working Capital | $25,078 (Current Assets $37,904 - Current Liab. $12,826) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 1.4% in the quarter and 5.9% year-to-date compared to 2006. International sales grew 13.4% in the quarter, driven by a 29.9% increase in refractive product sales. Conversely, U.S. sales declined 15.6% in the quarter.
- Profitability: While gross margins improved slightly due to a favorable product mix (higher margin ICLs), the Net Loss widened by 35.4% in the quarter and 19.7% year-to-date. This was driven by increased operating expenses and one-time costs.
- Expense Increases: Marketing and selling expenses rose 12.8% in the quarter, attributed to increased salaries, travel, and the timing of the ASCRS trade show. General and administrative expenses increased 9.8% due to audit-related costs and the investigation into the German subsidiary.
- Other Expenses: Other expense increased significantly due to a $233,000 loss on the extinguishment of a note payable to Broadwood Partners and a $232,000 write-off of deferred financing costs.
Guidance, Outlook, and Risks
- Capital Raise: On May 1, 2007, STAAR completed a public offering of 3.6 million shares at $5.00 per share, yielding approximately $16.8 million in net proceeds. These funds were used to repay a $4.0 million note to Broadwood Partners and a $1.8 million loan to UBS, with the remainder allocated to working capital and R&D.
- Strategic Shift: Management is restructuring its U.S. sales force, moving away from independent regional representatives to a direct sales model for refractive products (ICL) to accelerate market penetration. Two major independent contracts expired July 31, 2007, and were not renewed.
- Regulatory Risks (FDA):
- TICL Approval: The FDA placed the application for the Toric ICL (TICL) on "integrity hold" on August 3, 2007, requiring an independent third-party audit of clinical data before further review. This follows a June 26, 2007 Warning Letter regarding clinical study documentation.
- Compliance: The company continues to address historical FDA compliance issues, though recent inspections in 2006 found no new non-compliance observations.
- Internal Control Weakness: The company identified a material weakness in internal controls related to its German subsidiary, Domilens GmbH, following the discovery of asset misappropriation by the former president. Remediation efforts are ongoing, and disclosure controls were deemed ineffective as of the reporting date.
- Liquidity: Despite the equity raise, the company has a history of losses and negative operating cash flows. It expects to continue seeking additional financing to sustain operations until profitability is achieved.
Investor Verification Checklist
- FDA Status: Verify the timeline and outcome of the independent audit required for the TICL PMA supplement and the status of the June 2007 Warning Letter response.
- Sales Force Transition: Monitor the impact of the U.S. sales force restructuring on Q3 and Q4 revenue, specifically the risk of customer attrition during the transition from independent reps to direct sales.
- Internal Controls: Review the progress of remediation efforts regarding the material weakness in internal controls at the German subsidiary to ensure future financial reporting reliability.
- Cash Burn Rate: Assess whether the $16.8 million raised in May 2007 is sufficient to fund operations through the next 12-18 months given the continued operating losses and negative cash flow from operations.
- Product Mix: Track the growth rate of the Visian ICL in the U.S. market, as management identifies this as the primary driver for a return to profitability.